
|Videos|October 15, 2021
Dr. Tagawa on treatment patterns and survival in mCSPC
Author(s)Urology Times staff
Scott T. Tagawa, MD, discusses a study of treatment patterns and overall survival in metastatic castration-sensitive prostate cancer between 2006 and 2019.
Advertisement
Scott T. Tagawa, MD, discusses the background and results of the study, “Treatment patterns and overall survival in metastatic castration-sensitive prostate cancer from 2006 to 2019,” which was presented during the 2021 ESMO Congress.
Tagawa is a professor of Medicine and Urology at Weill Cornell Medicine, and an attending physician at NewYork-Presbyterian/Weill Cornell Medical Center.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves sildenafil oral film for men with erectile dysfunction
2
The UroOnc Minute: Adjuvant Therapy in Renal Cell Carcinoma, with Brian Shuch, MD
3
Head-to-head analysis shows OS benefit with apalutamide vs darolutamide in mCSPC
4
URO-1 prostate biopsy devices adopted across Novant Health System as clinical study continues
5






